New asthma drug under watch in korea
NCT ID NCT06998095
Summary
This study aims to monitor the safety and effectiveness of the asthma drug Tezspire (tezepelumab) in real-world medical practice in South Korea. It will follow 210 patients with severe asthma for 24 weeks to track any side effects and see if their asthma control improves. The goal is to understand how the drug performs outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.